| Baseline characteristics of two groups of patients | |||
|
| Intervention group (n = 57) | Control group (n = 66) | P value |
| Age |
|
| 1.189 |
| Median | 49 (30 - 70) | 47 |
|
| <35 | 7 (12.3) | 3 (4.5) |
|
| ≥35 | 50 (87.7) | 63 (95.5) |
|
| BMI |
|
| 2.246 |
| Normal | 36 (63.2) | 34 (51.5) |
|
| Abnormal | 21 (36.8) | 32 (48.5) |
|
| pT status |
|
| 0.048 |
| T1 | 19 (33.3) | 31 (47.0) |
|
| T2 | 36 (63.2) | 32 (48.5) |
|
| T3 | 2 (3.5) | 3 (4.5) |
|
| pN status |
|
| 0.087 |
| N0 | 24 (42.1) | 33 (50.0) |
|
| N1 | 19 (33.3) | 19 (28.8) |
|
| N2 | 5 (8.8) | 9 (13.6) |
|
| N3 | 9 (15.8) | 5 (7.6) |
|
| Stage |
|
| 0.284 |
| I | 12 (21.1) | 17 (25.8) |
|
| II | 30 (52.6) | 33 (50.0) |
|
| III | 15 (26.3) | 16 (24.2) |
|
| Molecular subtyping |
|
| 0.014 |
| Luminal A | 6 (10.5) | 6 (9.1) |
|
| Luminal B | 38 (66.7) | 46 (69.7) |
|
| HER-2 | 6 (10.5) | 6 (9.1) |
|
| TNBC | 7 (12.3) | 8 (12.1) |
|